Specific objectives:  1.3 TASKS, DELIVERABLES, TIMELINE AND PAYMENTS  4  If a subcontractor provides the whole or a very large part of the financial capacity OR executes the whole or a  very large part of the tasks, EFSA may demand the subcontractor to sign the contract.  5  No. Tasks & deliverables Can be  subcontracted? 4 Deadline 1  Task:  To develop a data model that will  contain chemical as well as all the biological  (ADME) and toxicological information and that  will be agreed by EFSA. The data model should  be fully compatible with the data model  developed as part of the ongoing project with  the Technical University of Denmark (DTU)  (GP/EFSA/PREV/2020/01). The data model to  be developed here should be expanded from  the model developed by DTU and should use  existing OECD OHT and IUCLID. For data  elements that cannot be codified in IUCLID or  through OHT, the contractors should propose  an appropriate data model. The data should  include all relevant chemical information (name, CAS, SMILES, Inchi) and all relevant  ADME information (relevant physicochemical  properties  (e.g.  logP),  bioavailability,  distribution,  Cmax,  metabolism,  half-life,  routes of elimination, etc… ). The data model  should  also  cover  relevant  toxicological  information from 28-d and 90-d studies. If  available  for  active  substance  and  Yes  3 months from kick-off  meeting  The objectives of the contract resulting from the present procurement procedure will be  as follows:  Objective 1: To identify and extract all existing biological (absorption, distribution,  metabolism, and excretion (ADME) and toxicological information from repeated-dose  toxicity studies for all active substances assessed by EFSA through the peer-review process  in Europe and their metabolites and/or degradation products from EFSA conclusions and  related risk assessment reports, using an agreed data model. Objective 2:  To identify and retrieve complementary mechanistic data (new approach  methodologies (NAM) data) for the substances identified in Objective 1, from the open  literature and other sources (e.g. Tox21, ToxCast, etc) that will reduce uncertainty in the  RAx.  Objective 3:  Once the information has been captured and curated in the database, the  substances to be studied will be analysed for RAx using (i) chemical structure determinants  and (ii) biological, toxicological and mechanistic information. Analogue and category  approaches will be assessed. This objective should provide an analysis of the parameters  and determinants necessary for a reliable and reproducible RAx. 